Latest News
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
10 July 2025 - US biogenetics company Klotho Neurosciences, Inc. (NASDAQ:KLTO) announced on Thursday that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to KLTO-202, its lead gene therapy candidate for the treatment of ...
European Commission approves TEVIMBRA with chemotherapy for first-line treatment of nasopharyngeal carcinoma
10 July 2025 - Oncology company BeOne Medicines Ltd (NASDAQ:ONC) (HKEX:06160) (SSE:688235) announced on Thursday that the European Commission has approved TEVIMBRA (tislelizumab) in combination with gemcitabine and cisplatin as a first-line treatment...
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
10 July 2025 - Needle-free injection technology company PharmaJet said on Thursday that it has signed a Memorandum of Understanding with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma to explore the integration of needle-free deliver...
Pfizer and Astellas report XTANDI plus leuprolide improves survival in high-risk prostate cancer patients
10 July 2025 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) and Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) on Thursday announced positive overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide...
MetaVia doses first patient in 48 mg MAD cohort of DA-1726 Phase 1 trial
10 July 2025 - MetaVia Inc (Nasdaq:MTVA), a US-based clinical-stage biotechnology company focused on cardiometabolic diseases, announced on Wednesday that the first patient has been dosed in the 48 mg, multiple ascending dose (MAD) cohort of its Phas...